Systemic therapy options in BRCA mutation-associated breast cancer.
about
Cytotoxic and targeted therapy for hereditary cancersNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionEvolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancersBRCA1 and BRCA2 mutations and treatment strategies for breast cancer.Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancerPredictive imaging of chemotherapeutic response in a transgenic mouse model of pancreatic cancerThe degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma.Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays.Skin cancer risk in BRCA1/2 mutation carriers.Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.Evaluation of psychosocial aspects in participants of cancer genetic counselingThe role of BRCA status on prognosis in patients with triple-negative breast cancer.Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
P2860
Q26739366-EE885538-86DB-47BA-845F-5E727251A6B4Q26851765-B3641BE0-EE83-415C-A6A1-DE3714C60F65Q28542563-C81CC9C4-FD75-45F9-BE54-9EE7A96E7A61Q33894431-B1216F36-2463-471C-8904-97C9FD946B35Q34113473-D6DCF18B-845A-4443-9A1C-59A1D3B0E746Q34946808-9EDCF43C-C96C-4CBD-8F5D-912D86525B94Q35647617-531A377E-C8EF-4B1E-8F92-496C852136F6Q35977371-FC821751-D9BC-41BC-9E0A-13D25FAAAD77Q36568348-93348B50-8AE0-40BE-8CC1-069538657E40Q37047682-0FCE25AA-B16F-45E2-8A51-61D7C916DE1DQ37488137-F1020697-BDCF-416B-8C37-C53CE1FDBEEEQ38068925-6D7AFEC7-6A00-4E52-8BB9-D3EECDB54189Q38294122-F9E5D2E2-5461-4F62-B3F0-8B602A3F1DF9Q38389226-6B5E01A3-609B-4A30-B565-793B5F6E4654Q38633504-AC92DF85-CA3F-46C0-AE8D-87C52317A059Q38806371-2F662323-459C-4655-9EB8-B0794E48F404Q39262474-0B8044DC-7C6D-4DDC-AB86-347225CDDA00Q41696212-0C1E19CD-AE42-4825-84F4-D9AA960049F2Q47097677-5D0475D8-1CAD-4141-903C-B326E6151190Q47159549-1FBB3A11-00CD-4A0F-BAAC-12743699D518Q48005561-A8640DBA-5567-49E2-93D8-EDC3E08BF25EQ48588785-5145F05D-A559-4057-988E-14A8B86B185AQ55518023-9B80B757-0773-4295-B3AA-14F137FD3C03
P2860
Systemic therapy options in BRCA mutation-associated breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Systemic therapy options in BRCA mutation-associated breast cancer.
@en
type
label
Systemic therapy options in BRCA mutation-associated breast cancer.
@en
prefLabel
Systemic therapy options in BRCA mutation-associated breast cancer.
@en
P2860
P1476
Systemic therapy options in BRCA mutation-associated breast cancer.
@en
P2093
Soley Bayraktar
Stefan Glück
P2860
P2888
P304
P356
10.1007/S10549-012-2158-6
P407
P577
2012-07-12T00:00:00Z
P5875
P6179
1001520525